peregrine pharmaceuticals, inc. (nasdaq: Pphm)
interim phase ii data presented at xiv world congress of neurological surgery supports potential of peregrine's cotara(r) for treatment of brain cancer
company overview
cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody designed to bind to the dna histone complex that is exposed by dead and dying cells found at the center of solid tumors. Cotara's targeting mechanism enables it to bind to the dying tumor cells, delivering its radioactive payload to the adjacent living tumor cells and essentially destroying the tumor from the inside out, with minimal radiation exposure to healthy tissue. Cotara is delivered using convection-enhanced delivery (ced), an nih-developed method that targets the specific tumor site in the brain. In a previous clinical study, a subset of patients with recurrent glioblastoma treated with cotara achieved a median survival of 38 weeks, a 58% increase over the historical median survival time of 24 weeks for patients treated with standard of care therapy. In this study, 25% of 28 recurrent patients survived for more than a year post-treatment and 10% of patients survived for more than three years. These data are considered a promising development in this deadly disease. In addition to the phase ii trial now underway in india, a dosimetry and dose confirmation trial in glioblastoma patients at leading u.s. Academic brain cancer centers is nearing completion. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the u.s. Food and drug administration.
About peregrine pharmaceuticals
peregrine pharmaceuticals, inc. Is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis c virus infection with its lead product candidates bavituximab and cotara(r). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary avid bioservices, inc. (
www.avidbio.com), which provides development and biomanufacturing services for both peregrine and outside customers. Additional information about peregrine can be found at
www.peregrineinc.com.
السهم للاستثمار جيد اذا نزل شوى زين عن الاسعار الحاليه ممتاز جلب بيه